Rheumatology Network's Top 5: October 22, 2021
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 22, 2021.
FDA Approves Adalimumab-adbm (Cyltezo), Interchangeable Biosimilar to Adalimumab
The US Food and Drug Administration (FDA) approved adalimumab-adbm (Cyltezo), the first interchangeable biosimilar to treat inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis.
Click the image to view the story.
Jeffrey Stark, MD: Safety and Efficacy of Bimekizumab as Psoriasis Treatment
Jeffrey Stark, MD, discusses the recent studies, BE BRIGHT, BE SURE, and BE VIVID, in which investigators analyzed the impact bimekizumab had on patients with psoriasis.
Click the image to view the story.
Steroid Injection Effectively Treats Psoriatic Hand Dactylitis
Dactylitis, a uniform swelling of an entire digit, occurs in up to half of patients with psoriatic arthritis and is sometimes the first manifestation of the condition.
Click the image to view the story.
Rheumatoid Arthritis Quiz: How do Drugs Affect Risk of Osteoporosis in RA?
Osteoporosis is a common comorbidity for patients with rheumatoid arthritis. How much do you know about how drugs impact bone health in rheumatoid arthritis?
Click the image to view the story.
Upadacitinib Improves Patient-Reported Outcomes in Patients With Psoriatic Arthritis
A significant number of patients with psoriatic arthritis fail to achieve adequate disease control, resulting in health-related quality of life (HRQOL) impairments.
Click the image to view the story.
